Research Paper Volume 16, Issue 1 pp 226—245

Figure 3. Prognostic analysis of RBMX in the pan-cancer setting. (A) Heatmap based on the univariate Cox proportional hazards regression and Kaplan–Meier models. The heatmap summarizes the correlation between RBMX expression and disease-specific survival (DSS), overall survival (OS), progression-free interval (PFI), and disease-free interval (DFI). Red and blue represent the risk and protective roles, respectively, in the prognosis of cancer. (B) Prognostic role of RBMX in the pan-cancer setting, illustrated by a forest plot based on the univariate Cox proportional hazards regression method. Red indicates the types of cancer for which RBMX was identified as significant risk factor. (C–F) Kaplan–Meier analysis indicated that higher RBMX expression was associated with worse clinical prognosis in LIHC (C) and KIRP (D). However, higher RBMX expression was predictive of better prognosis in KIRC (E) and READ (F). KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; RBMX, RNA binding motif protein X-linked; READ, rectum adenocarcinoma.